Article

PTBP1 drives immune dysfunction and predicts immunotherapy response in metastatic triple-negative breast cancer

2025-09-12

Abstract excerpt

<title>Abstract</title> <p>Triple-negative breast cancer (TNBC) is a subtype with limited treatment options and poor outcomes, particularly in the metastatic setting. Although immunotherapy has shown efficacy in early-stage disease, its benefit remains suboptimal in women with locally advanced and metastatic TNBC. Here, we identify the splicing factor PTBP1 as a tumor-intrinsic regulator of immune evasion in meta...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 58bb599e-0712-511b-a8da-4a4892a810a1
DOI: 10.21203/rs.3.rs-7355872/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

PTBP1 drives immune dysfunction and predicts immunotherapy response in metastatic triple-negative breast cancerDOI 10.21203/rs.3.rs-7355872/v1Read

The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.Semantic proximity Read

Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypesSemantic proximity Read

LSM4 drives the progression of triple-negative breast cancer through alternative splicingSemantic proximity Read

Transcriptomics and mutational analysis to screen immunogenic neoantigen peptides and Patient stratification based on immune subtypes for TNBCSemantic proximity Read

Comprehensive genomic profiling of triple-negative breast cancer metastases identifies role of PKD1 in immunotherapy resistance.Semantic proximity Read

A comprehensive analysis of immune landscape of Indian triple negative breast cancerSemantic proximity Read

Robust CRISPR Screens Identify TPL1 as a Novel Long Noncoding RNA Driving Triple-Negative Breast Cancer HallmarksSemantic proximity Read

Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype ShiftsSemantic proximity Read

How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategiesSemantic proximity Read

Immune landscape and risk prediction based on pyroptosis-related molecular subtypes in triple-negative breast cancerSemantic proximity Read

Integrated single-cell and bulk RNA sequencing identifies SERPING1 as an immune infiltration regulator and therapeutic target in Triple-negative breast cancerSemantic proximity Read

ZNF831 suppresses triple-negative breast cancer progression through NLRP3-associated pyroptotic signaling and M1-like macrophage phenotypic remodeling.Semantic proximity Read